Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Jens HuoberCarlos Henrique BarriosNaoki NiikuraMichal JarzabYuan-Ching ChangShannon L Huggins-PuhallaJosé PedriniLyudmila ZhukovaVilma GraupnerDaniel EigerVolkmar HenschelNino GochitashviliChiara LambertiniEleonora RestucciaHong Zhangnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Atezolizumab with neoadjuvant dose-dense doxorubicin/cyclophosphamide-paclitaxel and PH for high-risk, HER2-positive early breast cancer did not increase pCR rates versus placebo in the ITT or PD-L1-positive populations. PH and chemotherapy remains standard of care; longer follow-up may help to inform the long-term impact of atezolizumab.
Keyphrases
- epidermal growth factor receptor
- phase iii
- early breast cancer
- open label
- locally advanced
- tyrosine kinase
- double blind
- clinical trial
- advanced non small cell lung cancer
- endothelial cells
- placebo controlled
- phase ii
- rectal cancer
- lymph node
- healthcare
- induced pluripotent stem cells
- palliative care
- pluripotent stem cells
- high dose
- squamous cell carcinoma
- radiation therapy
- drug delivery
- study protocol
- randomized controlled trial
- low dose
- pain management
- cancer therapy
- cell therapy
- bone marrow